Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin
Brand Names: Texaclear Severe Cough, Cold and Flu
Methodology & AI Transparency ⓘ
Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Uses temporarily relieves these common cold and flu symptoms: Cough headache sore throat minor aches and pains temporarily reduces fever helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
- 2 Real-world patient consensus: 86% patient "Worth It" rating across 11 anonymous logs for Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin (RxNorm 2670541).
- 3 Typical cash cost range: Public pharmacy ledger: $145.39 low cash benchmark vs. $356.21 chain retail average ($3.3800/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin: headache (11.2%), cough (4.6%), nausea (8.3%).
Ask our AI Specialists anything about Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin
Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin Mechanism, CYP450 Pathways & DailyMed Monograph
Uses temporarily relieves these common cold and flu symptoms: Cough headache sore throat minor aches and pains temporarily reduces fever helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Biochemical activity of Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin (NDC 58809-217) reflects expectorant receptor or enzymatic engagement paired with $3.3800/unit CMS NADAC reference benchmarks.
With Approximately 3–9 hours terminal plasma half-life for Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin residence kinetics and Estimated 50%–62% oral systemic absorption for Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin bioavailability, Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin undergoes phase i/ii hepatic conjugation of choline salicylate, dextromethorphan hydrobromide, guaifenesin coupled with glomerular and tubular renal excretion and establishes therapeutic activity over peak plasma concentration (tmax) reached 1–4 hours post-dose for choline salicylate, dextromethorphan hydrobromide, guaifenesin.
Standard adult regimens span 870 mg/30mL / 20 mg/30mL Liquid, 30 mL. Prescribers screen specifically against prior anaphylaxis, angioedema, or severe hypersensitivity to choline salicylate, dextromethorphan hydrobromide, guaifenesin or choline salicylate, dextromethorphan hydrobromide, guaifenesin excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2025-10-06 choline salicylate, dextromethorphan hydrobromide, guaifenesin spl, while community micro-logs most frequently note headache (11.2% of reports), nausea (8.3% of reports), dizziness (6.7% of reports).
Avoid overlapping expectorant prescriptions alongside Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin to prevent cumulative receptor toxicity.
Botanical enzyme modulators may alter oral first-pass exposure of Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin or Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2025-10-06 Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin SPL
Logged Side-Effect Incidence (11 Reports)
Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Randomized Multicenter Study on the Impact of [ 18 F]F-Choline PET/CT Versus: What a 256-Participant Study Found [ 18 F]F-choline PET/CT reduced the rate of unnecessary extensive lymphadenectomy by up to 8%. Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2024-07-01 • Phase III Randomized Trial | N = 256 | 87/100 | PMID 38844361 ↗ |
| Can This Approach Help? Inside the Latest Research on 18F-PSMA-1007 and 18F-Choline PET/CT in prostate cancer patients with biochemical 18F-PSMA-1007 is more efficacious than 18F-Choline for the identification metastatic lesions both in patient and in regional level analysis in PCa patients with BCR. Nuclear medicine communications • 2023-12-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37779440 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase III Study of 18 F-PSMA-1007 Versus 18 F-Fluorocholine PET/CT for Conclusion: 18 F-PSMA-1007 PET/CT is superior to 18 F-fluorocholine PET/CT for the localization of PCa recurrence. Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2023-04-15 • Phase III Randomized Trial | N = 190 | 82/100 | PMID 36418170 ↗ |
Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.3800/unit (~$101.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $356.21 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $145.39 / mo | View logs ↓ |
Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin RxNorm Concept ID | 2670541 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.3800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $356.21 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $145.39 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin integrating DailyMed SPL (2025-10-06), CMS NADAC ($3.3800/unit), and 11 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Choline Salicylate, Dextromethorphan Hydrobromide, Guaifenesin community threads and patient logs by age, biological sex, dosage, and treatment duration.